Paper 32 - IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE VASCULAR SARCOMAS COHORT. A GEIS, ISG AND UCL STUDY.

Author(s)

• 

  Nadia Hindi, MD, MSc

  Medical Oncologist
  Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
  Madrid, Madrid, Spain

  Slides

Co-Author(s)

• JM

  Javier Martinez-Trufero, MD

  Medical Oncologist
  HU Miguel Servet
  Zaragoza, Aragon, Spain
• GG

  Giovanni Grignani, MD

  Candiolo Cancer Institute, FPO – IRCCS
  Turin, Piemonte, Italy
• 

  Ana Sebio, MD, PhD (she/her/hers)

  Consultant
  Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  Barcelona, Catalonia, Spain
• SS

  Sandra Strauss, MD, PhD

  University Collegue of London (UCL)
  London, England, United Kingdom
• 

  Silvia Stacchiotti, MD (she/her/hers)

  Consultant
  Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  Milano, Lombardia, Italy
• EG

  Enrique Gonzalez-Billalabeitia, MD

  Medical Oncologist
  HU Doce de Octubre
  Madrid, Madrid, Spain
• IC

  Irene Carrasco Garcia, MD

  Medical Oncologist
  Virgen del Rocio University Hospital
  Seville, Andalucia, Spain
• RR

  Rafael Ramos, MD, PhD

  HU Son Espases
  Palma Mallorca, Islas Baleares, Spain
• AG

  Antonio Gutierrez, MD, PhD

  HU Son Espases
  Palma, Islas Baleares, Spain
• 

  David S. Moura, PhD (he/him/his)

  Molecular biologist
  Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
  Madrid, Madrid, Spain
• PL

  Patricio Ledesma, .

  Sofpromed
  Palma de Mallorca, Islas Baleares, Spain
• JM

  Javier Martin-Broto, MD, PhD (he/him/his)

  Medical oncology
  Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
  Madrid, Madrid, Spain